Treatment‐Free Remission in CML
Symposium
Symposium

Treatment‐Free Remission in CML

Is It Time to Take the Leap?

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Meeting Overview

We are pleased to invite you to our satellite symposium, Treatment-Free Remission in CML: Is it Time to Take the Leap? to be held on Saturday, 14 October 2017, in conjunction with the 19th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy.

This satellite symposium has been designed to provide participants with an overview of current chronic myeloid leukemia (CML) treatment approaches in terms of success and challenges, including criteria to attempt treatment-free remission (TFR) and the appropriate patient selection for and management of patients in TFR.

Date and Location

Saturday, 14 October 2017
18.15 – 19.45

Auditorium
Estoril Congress Center
Avenida Amaral
Estoril, Portugal

Date/Time

Date/Time

Saturday, 14 October 2017
18.15 – 19.45

Location

Location

Estoril, Portugal

IME

IME

18.15 Welcome and introductions
Timothy Hughes, MD, FRACP, FRCPA, FAAHMS
18.20 Contemporary treatment of CML: Successes and challenges
Giuseppe Saglio, MD
18.35 The rationale and evidence for a TFR approach
Timothy Hughes, MD, FRACP, FRCPA, FAAHMS
18.55 From concept to practice: Practical implications and applications of TFR
Delphine Rea, MD, PhD
19.20 Faculty panel discussion
19.40 prIME Points
Timothy Hughes, MD, FRACP, FRCPA, FAAHMS
19.45 Adjourn

    Chair

  • Timothy Hughes, MD, FRACP, FRCPA, FAAHMSUniversity of Adelaide
    Adelaide, South Australia, Australia
  • Faculty

  • Delphine Rea, MD, PhDHôpital Saint-Louis
    Paris, France
  • Giuseppe Saglio, MDUniversity of Turin
    Turin, Italy

This educational activity is specifically designed to meet the needs of hematologists and other healthcare professionals involved in the treatment of patients with CML.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Upon completion of this educational activity, participants should be able to:

  • Describe clinical outcomes associated with current CML treatment approaches in terms of successes and challenges
  • Identify criteria for attempting TFR based on currently available evidence and discuss optimal treatment approaches for achieving these criteria
  • Discuss appropriate patient selection for TFR and management of patients in TFR

This educational activity is supported by a grant from Novartis Oncology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

EFPIA DISCLOSURE STATEMENT

prIME Oncology complies with all EFPIA Disclosure Code reporting requirements.

Disclosures

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.